Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-κB signal pathways

Clinical Cancer Research

Volumn 7, Issue 2, 2001, Pages 435-442

  Bancroft, C C ^a   Chen, Z ^a   Dong, G ^a   Sunwoo, J B ^a   Yeh, N ^a   Park, C ^a   Van Waes, C ^a  

^a Developmental Neuroscience Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOGENIC FACTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR KAPPA B KINASE; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE INDUCTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

BUTADIENES; CARCINOMA, SQUAMOUS CELL; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-8; LYMPHOKINES; MAP KINASE KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NITRILES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035124085     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer
2. Effects of interleukin-1α, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines
3. Interleukin-8 expression by head and neck squamous cell carcinoma
4. Cytokine expression by head and neck squamous cell carcinomas
5. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens
6. Local expression of antiinflammatory cytokines in cancer
7. The human gene for vascular endothelial growth factor
8. Cooperative interaction of nuclear factor-κB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by proinflammatory cytokines
9. Hepatitis B virus X protein transactivates the human interleukin-8 gene through acting on nuclear factor-κB and CCAAT/enhancer-binding protein-like cis-elements
10. Tumor necrosis factor α and interferon γ synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-κB-like binding sites of the interleukin 8 gene
11. Constitutive activation of transcription factors NF-(κ)B, AP-1. and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines
12. NF-κB: 10 years after
13. NF-κB activation: The 1κB kinase revealed?
14. Rel/NF-κ B/1κB family: Intimate tales of association and dissociation
15. Activation of nuclear transcription factor NE-κB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit
16. Regulation of NF-κB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Cζ in primary endothelial cells
17. Activation of NF-κB in vivo is regulated by multiple phosphorylations
18. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
19. Asynchronous modulation of transforming growth factor α and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma
20. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival
21. EGF receptor in neoplasia and metastasis
22. One-way cross-talk between p38(MAPK) and p42/44(MAPK)
23. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
24. MAPKs new JNK expands the group
25. Parallel signal processing among mammalian MAPKs
26. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells
27. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-α but not by 12-O-tetradecanoylphorbol-13-acetate
28. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
29. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades
30. Human T-cell leukemia virus type I Tax transactivates human interleukin-8 gene through acting concurrently on AP-1 and nuclear factor-κB-like sites
31. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of 1κBα: A mechanism for NF-κB activation
32. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
33. Cytokines in the immune pathogenesis and therapy of head and neck cancer
34. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells
35. Activation of ERK2 by respiratory syncytial virus in A549 cells is linked to the production of interleukin-8
36. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts
37. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma
38. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
39. Integrin ανβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
40. Low incidence of point mutation at codon 12 of K-ras proto-oncogene in squamous cell carcinoma of the upper aerodigestive tract
41. Low incidence of H-. K-. and N-ras oncogene mutations in cytological specimens of laryngeal tumors
42. Ras mutations and expression in head and neck squamous cell carcinomas
43. The role of peptide growth factors in head and neck carcinoma
44. TGF-α and EGFR in head and neck cancer
45. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer
46. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
47. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
48. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy
49. Fra-1, a pivotal player in the MAP kinase dependent activation of AP-1 and neoplastic transformation
50. Activation of NF-κB by oncogenic Ras and Raf contributes to cellular transformation